Skip to content

Use of bioactive glass BAG-S53P4 for the treatment of chronic osteomyelitis of the long bones.

Use of bioactive glass BAG-S53P4 for the treatment of chronic osteomyelitis of the long bones.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00005332
Enrollment
30
Registered
2013-09-27
Start date
2010-11-04
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M86.6 M86.3

Interventions

Group 1: Patients treated with BAGS53P4

Sponsors

IRCCS Galeazzi Orthopaedic Institute
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Presence of osteomyelitis of a long bone for at least 6 months requiring surgical debridement and bone defect filling

Exclusion criteria

Exclusion criteria: Need for local plastic procedures, segmental bone defects, associated septic arthritis.

Design outcomes

Primary

MeasureTime frame
Absence of infection recurrence/persistence at follow-up, defined as: absence of draining sinus or local clinical signs of acute inflammation (redness, swelling, warmth, pain), elevated values of C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and no need for further surgery whenever during follow-up. Time visits for follow-up are: 15 and 30 days and 3, 6, 9, 12, 18, 24 months after surgery.

Secondary

MeasureTime frame
Absence of local or systemic side effects connected with the use of the BAG.

Countries

Italy

Contacts

Public ContactCarlo L. Romanò

IRCCS Galeazzi Orthopaedic Institute

carlo.romano@grupposandonato.it00390266214743

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 22, 2026